ChemPartner PharmaTech Co.,Ltd. (SHE:300149)
China · Delayed Price · Currency is CNY 9.52
+0.41 (4.50%)
At close: Aug 4, 2026
ChemPartner PharmaTech Revenue
ChemPartner PharmaTech had revenue of 266.69M CNY in the quarter ending March 31, 2026, with 2.08% growth. This brings the company's revenue in the last twelve months to 1.14B, up 14.37% year-over-year. In the year 2025, ChemPartner PharmaTech had annual revenue of 1.13B with 16.96% growth.
Revenue (ttm)
1.14B
Revenue Growth
+14.37%
P/S Ratio
3.98
Revenue / Employee
643.79K
Employees
1,771
Market Cap
4.54B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.13B | 164.51M | 16.96% |
| Dec 31, 2024 | 970.20M | -168.16M | -14.77% |
| Dec 31, 2023 | 1.14B | -188.22M | -14.19% |
| Jan 1, 2023 | 1.33B | -364.09M | -21.54% |
| Jan 1, 2022 | 1.69B | 209.09M | 14.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Suzhou Fengbei Biotech Stock | 3.61B |
| Anhui Huaheng Biotechnology | 2.95B |
| Wuhan Hvsen Biotechnology | 1.74B |
| Xiangxue Pharmaceutical | 1.53B |
| Shenzhen Weiguang Biological Products | 1.26B |
| Beijing Konruns Pharmaceutical | 917.99M |
| R&G PharmaStudies | 896.26M |
| Beijing Bohui Innovation Biotechnology Group | 812.78M |